Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology

Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.

Filter by

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology

Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) GI

Jun 26
- Jun 29, 2024
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
Kasi, et. al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society of Clinical Oncology (ASCO)

May 31
- Jun 4, 2024
Botensilimab (BOT) plus balstilimab (BAL) in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites
Fakih, et al.
AGEN1777

American Association of Cancer Research (AACR)

Apr 5
- Apr 10, 2024
BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models
Chand, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society for Clinical Oncology (ASCO) GI

Jan 18
- Jan 20, 2024
Neoadjuvant botensilimab plus balstilimab (BOT/BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
Kasi, et. al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Oncoimmunology

Nov 5, 2023
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 21, 2023
Efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Connective Tissue Oncology Society (CTOS)

Oct 13, 2023
Efficacy and safety of Botensilimab plus Balstilimab combination therapy in refractory metastatic sarcoma patients: findings from an ongoing expanded phase 1b study
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Oncogene

Sep 21, 2023
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) GI

Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Phosphopeptide Targets

Nature Communications

Jun 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicity
AGEN2373 (CD137 Agonist)

American Society of Clinical Oncology (ASCO)

Jun 3, 2023
A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors
Barve et al.